生命科学资讯

‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific

FDA fleshes out new roadmap for testing personalized therapies

Astellas pays $240M cash for Vir's prostate cancer drug

QurAlis' ALS drug sees early positive signal, but questions remain

Angelini nocks an AI arrow with $120M Quiver Bioscience deal

UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies

Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act

Fortress to sell priority review voucher for $205M

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

Appointments and advancements for Feb. 23, 2026

Financings for Feb. 23, 2026

In the clinic for Feb. 23, 2026

Other news to note for Feb. 23, 2026

Regulatory actions for Feb. 23, 2026

FDA unveils long-awaited guidance on new pathway for individualized therapies

Flagship's Generate targets $2B+ valuation with Nasdaq IPO

AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago

FDA issues safety alert on Trividia blood glucose monitors

Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials

Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail